Models for Describing Relations Among the Various Statin Drugs, Low-Density Lipoprotein Cholesterol Lowering, Pleiotropic Effects, and Cardiovascular Risk††Conflicts of interest: In the past 2 years, Dr. Robinson has received grants from Abbott Laboratories, Abbott Park, Illinois, Astra-Zeneca, Wilmington, Delaware, Bristol-Myers Squibb, Princeton, New Jersey, GlaxoSmithKline, Pittsburgh, Pennsylvania, Hoffman La Roche, Basel, Switzerland, Merck & Company, West Point, Pennsylvania, Pfizer, New York, New York, Procter & Gamble, Cinncinnati, Ohio, Sankyo, Parsippany, New Jersey, Schering-Plough, Kenilworth, New Jersey, and Takeda Pharmaceuticals, Lincolnshire, Illinois and honoraria for education programs from Merck & Company, and has been a consultant and advisory board member for Merck Schering Plough.
- 1 April 2008
- journal article
- review article
- Published by Elsevier in The American Journal of Cardiology
- Vol. 101 (7) , 1009-1015
Abstract
No abstract availableKeywords
This publication has 51 references indexed in Scilit:
- Effect of High-Dose Atorvastatin on Hospitalizations for Heart FailureCirculation, 2007
- Meta-Analysis: The Effect of Statins on AlbuminuriaAnnals of Internal Medicine, 2006
- The Nonlipid Effects of Statins on Endothelial FunctionTrends in Cardiovascular Medicine, 2006
- Pleiotropic Effects of Statins: Benefit Beyond Cholesterol Reduction?JACC, 2005
- Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statinsThe Lancet, 2005
- The Potential Relevance of the Multiple Lipid-Independent (Pleiotropic) Effects of Statins in the Management of Acute Coronary SyndromesJACC, 2005
- Statins and Blood CoagulationArteriosclerosis, Thrombosis, and Vascular Biology, 2005
- Effects of statins on vascular structure and function: A systematic reviewThe American Journal of Medicine, 2004
- High-Dose Statins in Acute Coronary SyndromesJAMA, 2004
- Antiatherothrombotic Properties of StatinsJAMA, 1998